Last Updated on October 15, 2024 by The Health Master
Bengaluru: The US Food and Drug Administration (USFDA) said it does not intend to make any new guidance on the use of the popular cannabis compound CBD in food and supplements, saying the United States needs to develop a new framework to ensure its safe use.
The health regulator said it would work with Congress to develop a new, cross-agency regulatory framework. The USFDA denied three citizen petitions that had requested the agency provide guidance.
The agency said the current safety standards for dietary supplements or food additives are not appropriate for cannabidiol, based on data and studies it has reviewed and conducted.
“We have not found adequate evidence to determine how much CBD can be consumed and for how long, before causing harm,” USFDA Principal Deputy Commissioner Janet Woodcock said.
Cannabidiol is a non-psychoactive compound derived from cannabis. Long-term use of the compound has raised several safety concerns, including potential harm to the liver and to the male reproductive system.
The USFDA has generally pursued limited enforcement activity regarding CBD, focusing primarily on food and beverage products that make unsubstantiated health claims.
The USFDA said that the available data did not show how CBD products could meet the safety standard for substances in animal food, and it did not intend to provide new rules allowing the use of the compound in animal food either.
“A new regulatory pathway for CBD is needed that balances individuals’ desire for access to CBD products with the regulatory oversight needed to manage risks,” the agency said.
Cannabis products, excluding Jazz Pharmaceuticals Plc’s epilepsy drug Epidiolex, are illegal at the federal level in the United States, although some states allow their use.
CDSCO Panel nod for Cholecalciferol Aqueous Injection
USFDA approves this drug for rare blood cancer
USFDA issues zero observations for Gland Pharma API Facility
Maha FDA: Action on illegal sale of drugs misused for body building
Drug: Recall: 10,052 bottles of Levofloxacin tablets recalled due to this reason
CDCSO Panel gives nod to market for Ocrelizumab
Area required for manufacturing of Drugs, Cosmetics, Homoeopathic & Blood Centre
Drug recall: Bharat Biotech voluntarily recalls ChiroRaba vaccine due to this…
Medical device: Industry seeks clarity on misbranded and adulterated devices
BA / BE Studies: Bioavailability & Bioequivalence
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon: